Death tumor cells or help tumors "come back"!

(Special correspondent Yuan Wei at Renji Hospital, affiliated with Shanghai Jiaotong University Medical School)
May 8, 2017, the most authoritative international journal of immunology, Nature Reviews Immunology (IF-39.416), published online a paper entitled "Immunelifelife life cell in cancer" written by professor Xia Qiang, director of liver surgery at Renji Hospital, shanghai Jiaotong University, online.
clinical treatment methods are difficult to eliminate all tumor cells
the first author of this paper, Renji Hospital liver surgery resident Dr. Hou Jiajie introduced: in the process of tumor progression, the current clinical treatment methods are difficult to eliminate all tumor cells. The reason is, on the one hand, that the genetic and biological characteristics of tumor cells are related to them, and on the other hand, the regional environment on which tumor cells depend is also responsible.
, does the death of tumor cells mean the end of tumor biological events? The answer to this question may seem obvious, but it is not. The team's study showed that incomplete cell necrosis in tumor lesions reshaped its immune microenvironment, allowing residual tumor cell seeds to "burn endlessly and spring breezes to re-create."
the paper emphasizes that in-depth study of the way tumor cell death and its impact on the immune system, and fully consider the tumor local, regional and systemic immune state, for liver cancer, such as refractory tumor, is conducive to clinicians accurate analysis of the dynamic composition of tumor cells themselves, so as to more effectively implement precision treatment and combination therapy, in order to benefit the long-term survival of tumor patients.
the "master and pie" anti-cancer cell transformation to help tumor cells come back
talk about the theoretical basis of the formation of the thesis, Hou Jiajie, he said that if the human body's process against tumors is compared to the "envelopment war", then the immune microenvironment has two forces: "main battle faction" and "master and pie". "Main battle faction" is an effective immune cell with anti-tumor activity, they can play immune surveillance, killing and other functions; The main and pedicos" are myelin or lymphocyte cells that have immunosuppressive effects and can promote tumor progression by disrupting immune warfare. In fact, these "master and pie" cells in the early stage swell swells the body's "public security", some of them are responsible for antigen presentation, some are responsible for immune surveillance, belonging to the anti-cancer "united front." As the war on cancer enters the phase of rivalry, some unfirmly determined middlemen compromise or change in the process of "enemy" attack and "predatory resources". In the event of an immune attack or clinical treatment, necrotic tumor cells can form a "political ecology" suitable for tumor cells to survive and expand by releasing a variety of soluble factors "bribes" and "counter-reaction" to the above-mentioned centrist cells.
Professor Guido Kroemer, a member of the French Academy of Sciences and a nasal ancestor in the field of cell death and immunity, gave the paper a high rating. In particular, he noted that cell death outcomes in tumor treatment are critical to the patient's long-term prognosis, which depends largely on the establishment of immunosurveillance, and that Xia Qiang's team's innovative academic view of "immunesuppress celllife" and the call for precision therapy and combination therapy are of great significance in the field of tumor transformation research.
According to Professor Xia Qiang, dr. Hou Jiajie, 31, studied the basis and clinical strategy of tumor immunotherapy at Johns Hopkins Hospital Cancer Center in the United States, and applied for a national invention patent for the conversion of liver cancer immunity after returning home, and established the Shanghai Municipal Education Commission Morning Light Program, the National Natural Science Foundation project, etc. At present, Xia Qiang, Dr. Hou Jiajie led the liver cancer immunosuppressive series of research groups and domestic and foreign oncologists have also established a strategic cooperative relationship, this series of research work is expected to provide an important theoretical basis and practical experience for the development and innovation of liver cancer immunotherapy.
.